



# Our **DIGITAL HEALTH** Service

## Fact sheet

### ieMR System Improvements – updated General Adult Intravenous Iron PowerPlans

Two new General Adult Intravenous Iron Infusion PowerPlans are scheduled to be released on Tuesday 14<sup>th</sup> April 2020.

-  Iron Intravenous Carboxymaltose Infusion Adult
-  Iron Intravenous Polymaltose Infusion Adult




The new General Adult Iron Infusion PowerPlans were developed with clinical input and extensive engagement from all the General Medicine Clinical Network. It replaces the old Intravenous Iron – Adult PowerPlan.

**For any patients with previously planned Iron – Adult PowerPlans, these will remain active within the patient’s chart until administered/completed or discontinued.**

#### The improvements include:

- Separating the General Adult Intravenous Iron PowerPlans based on type of iron (i.e. iron carboxymaltose and iron polymaltose)
- The persistent clinical notes have been updated slightly with useful clinical information (e.g. recommendations to minimise risk of extravasation)
- Updated iron carboxymaltose order to better prompt the prescriber to consider patient’s current weight and prescribe appropriately
- Inclusion of the optional pre-medications and infusion reaction medications within each iron phase to improve prescribing workflow

#### What is changing?

- The previous Intravenous Iron – Adult PowerPlan has been replaced by three different PowerPlans to improve intravenous iron prescribing;
  -  Iron Intravenous Carboxymaltose Infusion Adult
  -  Iron Intravenous Polymaltose Infusion Adult
  -  Iron Infusion Maternity

#### Before

Intravenous Iron - Adult

- Assessment Phase (Planned Pending)
- Adult - Iron Polymaltose (Planned Pending)
- Adult - Iron Carboxymaltose (Planned Pending)
- Maternity - Iron Carboxymaltose (Planned Pending)
- Dialysis - Iron Infusion (Planned Pending)
- Infusion Reactions (Planned Pending)
- Disclaimer (Planned Pending)

#### After

Iron Intravenous Carboxymaltose Infusion Adult

- Iron Carboxymaltose Infusion (Planned Pending)
- Disclaimer (Planned Pending)

Iron Intravenous Polymaltose Infusion Adult

- Iron Polymaltose Infusion (Planned Pending)
- Disclaimer (Planned Pending)

For support call Digital Health Clinical Consultation Services 3176 8800

- The clinical information within the two new Iron Intravenous Adult PowerPlans has been reviewed and updated to include key clinical guidance. Additions include:
  - Recommendation to carefully consider need for parenteral iron
  - Recommendation to consider recent administration of packed red blood cells when calculating parenteral iron requirement
  - Reference to the Ganzoni formula
  - Recommendations to reduce extravasation risk

After

**Iron Intravenous Polymaltose Infusion Adult, Iron Polymaltose Infusion (Planned Pending)**

- Please refer to local procedures and guidelines for prescription and administration of this medication
- Parenteral iron is rarely indicated; however in some patients who cannot absorb sufficient iron orally, intravenous iron is the preferred route. However, intravenous iron can cause local reactions and subcutaneous discoloration frequently occur at the injection site
- The choice of the appropriate intravenous iron preparation depends on the individual patient and location of administration

Ganzoni formula: Iron dose (mg) = (weight [target Hb - actual Hb] x 0.24) + iron depot

Consider reducing calculated iron dose if the patient has recently received packed red blood cells (1 unit PRBC = 250 mg elemental iron)

**Line Insertion**

Extravasation of intravenous iron can cause permanent skin discoloration. Cannula should be placed in a large vein away from joint folds to reduce the risk of extravasation frequently during this time

- The Iron Intravenous Carboxymaltose Adult PowerPlan contains a single uplifted iron carboxymaltose order with filtered order sentences depending on the patient's weight (if recently documented). The previous PowerPlan contained two different iron carboxymaltose orders and the prescriber was required to manually select the most appropriate order.

Before

Adults <66kg  
 ferric carboxymaltose Select an order sentence

Adults >66kg  
 ferric carboxymaltose Select an order sentence

After

maltose) 20 mg/kg, Injection, IV, ONCE only, Indication: Iron deficiency anaemia  
 MAX 1000 mg /week Dilute in appropriate volume of sodium chloride 0.9%. Note: Dilute  
 ions for patients w 20 mg/kg, Injection, IV, ONCE only, Indication: Iron deficiency anaemia Less Than 50  
 1,000 mg, Injection, IV, ONCE only, Indication: Iron deficiency anaemia Greater Than

- Both the pre-medications and infusion reaction medications are now contained within each iron phase to improve prescriber workflow

Before

Intravenous Iron - Adult

- Assessment Phase (Planned Pending)
- Adult - Iron Polymaltose (Planned Pending)
- Adult - Iron Carboxymaltose (Planned Pending)
- Maternity - Iron Carboxymaltose (Planned Pending)
- Dialysis - Iron Infusion (Planned Pending)
- Infusion Reactions (Planned Pending)**
- Disclaimer (Planned Pending)

After

Within each iron phase:

**Pre Medications**

- Consider pre-medication
  - hydrocortisone
  - cetirizine
  - loratadine

**Infusion Reactions**

For support call Digital Health Clinical Consultation Services 3176 8800